Rifampicin
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Rifampicin: From Tuberculosis to Conjunctivitis
One-Sentence Summary
Rifampicin is a rifamycin-class antibiotic originally developed for tuberculosis and other mycobacterial infections. The TxGNN model predicts it may be effective for Conjunctivitis, with 0 clinical trials and 20 publications currently supporting this direction — most of the literature is historical, microbiological, or mechanistic rather than confirmatory treatment trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Tuberculosis (Mycobacterium tuberculosis infection) — based on established clinical knowledge; no market license record available in the current dataset |
| Predicted New Indication | Conjunctivitis |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L4 |
| India Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, Rifampicin is a rifamycin-class antibiotic that inhibits bacterial DNA-dependent RNA polymerase, and its efficacy against Mycobacterium tuberculosis and other susceptible organisms (including Chlamydia trachomatis and several Gram-positive bacteria) has been well established for decades.
Conjunctivitis — particularly bacterial and chlamydial forms — shares a plausible mechanistic link with rifampicin’s known antibacterial spectrum. The strongest supporting evidence is a 1975 controlled trial in Tunisia that compared topical rifampicin ointment against tetracycline and boric acid for endemic trachoma (a chlamydial conjunctivitis), showing measurable antibacterial activity. Several older case reports and reviews (e.g., meningococcal conjunctivitis treated with systemic rifampin, ophthalmic use reviews from the 1970s) reinforce that rifampicin has occasionally been used off-label for ocular infections.
However, most of the remaining literature consists of pathogen susceptibility surveys and case reports rather than treatment-outcome studies, and modern first-line therapy for bacterial/chlamydial conjunctivitis has largely shifted to safer topical antibiotics (e.g., fluoroquinolones, azithromycin). The prediction is mechanistically plausible but not supported by any contemporary clinical trial specifically targeting conjunctivitis.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 1096630 | 1975 | RCT (historical) | American Journal of Ophthalmology | Controlled trial: topical 1% rifampicin ointment vs. tetracycline vs. boric acid for endemic trachoma in Tunisian schoolchildren; rifampicin showed antibacterial activity comparable to tetracycline |
| 6635446 | 1983 | Review | Reviews of Infectious Diseases | Rifampin is the most active antibiotic against C. trachomatis by weight; effective for topical trachoma and male urethral infection, but resistance emerges easily in vitro |
| 5005929 | 1971 | Review | Annals of Ophthalmology | Early review discussing rifampicin’s role in ophthalmic infections |
| 15228931 | 2004 | Review | Anales de Pediatría | Reviews prevalent bacterial pathogens in conjunctivitis and their antibiotic sensitivity patterns |
| 19941479 | 2010 | Review | Current Medicinal Chemistry | Discusses neglected bacterial diseases including trachoma; notes rifampin/streptomycin combination use for Buruli ulcer |
| 33457332 | 2020 | Microbiology/susceptibility survey | Advanced Biomedical Research | Assessed bacterial etiology and antibiotic susceptibility of conjunctivitis isolates in Iran |
| 21484175 | 2011 | Bacteriologic survey | Journal of Ophthalmic Inflammation and Infection | Characterized bacterial etiologies and antibiotic resistance patterns of conjunctivitis in Nigeria |
| 21191558 | 2010 | Susceptibility survey | Revista Española de Quimioterapia | Antibiotic susceptibility of Corynebacterium macginleyi strains causing conjunctivitis |
| 8363150 | 1993 | Retrospective microbiologic study | Anales Españoles de Pediatría | Analyzed 50 neonatal conjunctivitis samples; found high antibiotic sensitivity except to penicillin |
| 14686993 | 2003 | Case report | Clinical Microbiology and Infection | Primary meningococcal conjunctivitis in a child successfully treated with systemic rifampin after topical therapy failed |
Safety Considerations
Drug Interactions: Rifampicin has 256 recorded drug-drug interactions in the dataset (source: DDInter), most rated Moderate severity. Notable interacting agents include:
- Proton pump inhibitors: Omeprazole, Rabeprazole
- Corticosteroids: Hydrocortisone, Dexamethasone, Betamethasone, Triamcinolone
- Antidiabetics: Metformin, Pioglitazone, Canagliflozin, Chlorpropamide
- Antibiotics: Doxycycline, Clarithromycin, Metronidazole
- Vitamin D analogs: Cholecalciferol, Calcifediol, Calcitriol
- Others: Bupropion, Aprepitant, Morphine, Picosulfuric acid
This reflects rifampicin’s well-known role as a strong CYP450 (and transporter) inducer, which reduces plasma concentrations of many co-administered drugs. Given the large interaction count (256 total), a full interaction screen against the patient’s concurrent medications is essential before use in any indication, including conjunctivitis.
Conclusion and Next Steps
Decision: Hold
Rationale: The only directly relevant clinical evidence is a single 1975 trial for trachoma (a specific chlamydial conjunctivitis), and the remaining 19 references are largely microbiological surveys, case reports, and mechanism reviews rather than confirmatory treatment studies. No trials have evaluated rifampicin against modern standard-of-care topical antibiotics for general bacterial conjunctivitis.
To proceed, the following is needed:
- TFDA/regulatory label warnings and contraindications (currently a blocking data gap — required before any safety pre-assessment)
- Confirmed mechanism of action documentation from DrugBank
- A prospective or retrospective comparative study of rifampicin vs. current first-line topical antibiotics specifically for bacterial/chlamydial conjunctivitis
- Clarification on route of administration (topical vs. systemic) appropriate for an ocular indication, given rifampicin’s systemic interaction burden
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.